Oxyntomodulin vs Pramlintide

Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.

An endogenous peptide produced in the gut that activates both GLP-1 and glucagon receptors. Dual receptor activation produces appetite suppression plus increased energy expenditure — a combination not achievable with GLP-1 agonists alone.

Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

FDA-approved synthetic amylin analogue that complements insulin therapy. Reduces postprandial glucose spikes and suppresses appetite, aiding weight management in T1D and T2D.